Trial Profile
Treatment with Endothelinantagonist to tcpc patients; a multicenter, randomized, Prospective study measuring maximal O2 uptake in ergometer bicycle test
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Bosentan (Primary)
- Indications Congenital heart defects
- Focus Therapeutic Use
- Acronyms TEMPO
- 05 Mar 2013 Status changed from recruiting to completed as reported by European Clinical Trials Database record.
- 09 Nov 2012 Actual initiation date (12 Nov 2010) added as reported by European Clinical Trials Database record.
- 23 Mar 2012 New trial record